Champions Oncology (CSBR) Other Non-Current Liabilities (2011 - 2026)
Champions Oncology (CSBR) posted quarterly Other Non-Current Liabilities of $7000.0 for Q2 2026, down 91.76% year-over-year from $85000.0 in Q2 2025, and down 74.07% quarter-over-quarter from $27000.0 in Q1 2026.
Champions Oncology (CSBR) Other Non-Current Liabilities (2011 - 2026) Analysis & Trends
Champions Oncology's Other Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $7000.0 for Q2 2026.
- In Q2 2026, Other Non-Current Liabilities fell 91.76% year-over-year to $7000.0; the TTM figure through Apr 2026 stood at $7000.0 (down 91.76% YoY), while the FY2026 annual figure was $7000.0, down 91.76% from the prior year.
- Other Non-Current Liabilities for Q2 2026 stood at $7000.0, down from $27000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $660000.0 in Q3 2022, with the low at $7000.0 in Q2 2026.
- The 5-year median for Other Non-Current Liabilities is $377000.0 (2022), against an average of $337666.7.
- The sharpest annual moves came in 2022 and 2026: Other Non-Current Liabilities jumped 172.73% in 2022, then plunged 91.76% in 2026.
- Champions Oncology's Other Non-Current Liabilities stood at $624000.0 in 2022, then declined by 23.72% to $476000.0 in 2023, then tumbled by 31.93% to $324000.0 in 2024, then tumbled by 85.8% to $46000.0 in 2025, then plunged by 84.78% to $7000.0 in 2026.
- Business Quant data shows CSBR's Other Non-Current Liabilities at $7000.0 in Q2 2026, $27000.0 in Q1 2026, and $46000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 7,000.00 |
| Jan 31, 2026 | 27,000.00 |
| Oct 31, 2025 | 46,000.00 |
| Jul 31, 2025 | 66,000.00 |
| Apr 30, 2025 | 85,000.00 |
| Jan 31, 2025 | 285,000.00 |
| Oct 31, 2024 | 324,000.00 |
| Jul 31, 2024 | 363,000.00 |
| Apr 30, 2024 | 401,000.00 |
| Jan 31, 2024 | 439,000.00 |
| Oct 31, 2023 | 476,000.00 |
| Jul 31, 2023 | 514,000.00 |
| Apr 30, 2023 | 551,000.00 |
| Jan 31, 2023 | 588,000.00 |
| Oct 31, 2022 | 624,000.00 |
| Jul 31, 2022 | 660,000.00 |
| Apr 30, 2022 | 391,000.00 |
| Jan 31, 2022 | 231,000.00 |
| Oct 31, 2021 | 235,000.00 |
| Jul 31, 2021 | 242,000.00 |